Array surges on with compelling colon cancer results

22 May 2019
array-big

Shares in Array Biopharma closed up 23% on Tuesday and have now almost doubled in the year-to-date.

The reason for the latest jump was the Colorado-based company presenting positive results from the interim analysis of the Phase III BEACON CRC trial.

"I believe the results of the trial will be practice-changing"This study is evaluating the combination of Braftovi (encorafenib), a BRAF inhibitor, Mektovi (binimetinib), a MEK inhibitor, and the Merck KGaA (MRK: DE) and Eli Lilly (NYSE: LLY) drug Erbitux (cetuximab), in BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two prior lines of therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology